The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study

This study aimed to investigate the influence of androgen deprivation therapy (ADT) for the development of dry eye disease (DED) in subjects with prostate cancer via the use of national health insurance research database (NHIRD) of Taiwan. A retrospective cohort study was conducted and patients were selected as prostate cancer with ADT according to diagnostic and procedure codes. Each participant in that group was then matched to one patient with prostate cancer but without ADT and two subject s without prostate cancer and ADT. And a total of 1791, 1791 and 3582 participants were enrolled in each group. The primary outcome was set as the DED development according to the diagnostic codes. Cox proportional hazard regression was applied to calculate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of ADT and other parameters for DED development. There were 228, 126 and 95 new events of DED developed in the control group, the prostate cancer without ADT group and the prostate cancer with ADT group. The rate of DED in the prostate cancer with ADT group (aHR: 0.980, 95% CI: 0.771-1.246, P= 0.8696) and Prostate cancer without ADT group (aHR: 1.064, 95% CI: 0.855-1.325, P= 0.5766) were not significantly different compared to the control group. In addition, the patients aged 70-79 years old demonstrated a significantly higher incidence of developing DED compared to those aged 50-59 years old (aHR: 1.885, 95% CI: 1.188-2.989, P= 0.0071). In conclusion, the use of ADT did not alter the incidence of subsequent DED.

[1]  Youqing Wang,et al.  Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019 , 2022, Frontiers in Public Health.

[2]  J. Bastarache,et al.  Androgen receptor signaling promotes Treg suppressive function during allergic airway inflammation , 2022, The Journal of clinical investigation.

[3]  S. Priyadarsini,et al.  Sex Hormones, Growth Hormone, and the Cornea , 2022, Cells.

[4]  D. Serban,et al.  Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer – A Review , 2021, In Vivo.

[5]  Shun-Fa Yang,et al.  The impact of receptor of advanced glycation end‐products polymorphisms on prostate cancer progression and clinicopathological characteristics , 2021, Journal of cellular and molecular medicine.

[6]  J. Vehof,et al.  The association between visual display terminal use and dry eye: a review , 2021, Acta ophthalmologica.

[7]  Yingping Deng,et al.  Prevalence of dry eye in patients with systemic lupus erythematosus: a meta-analysis , 2021, BMJ Open.

[8]  Shun-Fa Yang,et al.  Associations between LncRNA MALAT1 Polymorphisms and Lymph Node Metastasis in Prostate Cancer , 2021, Diagnostics.

[9]  J. Schoones,et al.  Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review , 2021, International journal of urology : official journal of the Japanese Urological Association.

[10]  P. Mercier,et al.  Targeting androgen-signaling in ILC2s protects from IL-33-driven lung inflammation, independently of KLRG1. , 2021, The Journal of allergy and clinical immunology.

[11]  V. Perez,et al.  Inflammatory basis for dry eye disease flares. , 2020, Experimental eye research.

[12]  Yingping Deng,et al.  The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies. , 2020, Endocrine journal.

[13]  Xiaohong Li,et al.  Effects of Disability Type on the Association between Age and Non-Communicable Disease Risk Factors among Elderly Persons with Disabilities in Shanghai, China , 2020, International journal of environmental research and public health.

[14]  T. Gourdin.  Recent progress in treating advanced prostate cancer. , 2020, Current opinion in oncology.

[15]  Rabab A Moussa,et al.  Dry eye in rheumatoid arthritis: relation to disease activity , 2020, Immunological medicine.

[16]  D. Siemens,et al.  Androgen Deprivation Therapy and Mental Health: Impact on Depression and Cognition. , 2020, European urology focus.

[17]  Yi-Zhong Chen,et al.  The relationship between androgen deprivation therapy and depression symptoms in patients with prostate cancer , 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.

[18]  M. Roe,et al.  Androgen deprivation therapy and cardiovascular disease. , 2020, Urologic oncology.

[19]  Shun-Fa Yang,et al.  Gout as a Risk Factor for Dry Eye Disease: A Population-Based Cohort Study , 2019, Journal of clinical medicine.

[20]  N. Tananuvat,et al.  A Randomized Controlled Double-Masked Study of Transdermal Androgen in Dry Eye Patients Associated With Androgen Deficiency. , 2019, American journal of ophthalmology.

[21]  Takefumi Yamaguchi.  Inflammatory Response in Dry Eye. , 2018, Investigative ophthalmology & visual science.

[22]  E. Crawford,et al.  Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations , 2018, Prostate Cancer and Prostatic Diseases.

[23]  S. Egawa,et al.  Epidemiology of prostate cancer in Asian countries , 2018, International journal of urology : official journal of the Japanese Urological Association.

[24]  P. Thulasi,et al.  Update in Current Diagnostics and Therapeutics of Dry Eye Disease. , 2017, Ophthalmology.

[25]  Yuliang Wang,et al.  Evaluation of a novel dry eye model induced by oral administration of finasteride , 2017, Molecular medicine reports.

[26]  D. Schaumberg,et al.  Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. , 2017, American journal of ophthalmology.

[27]  D. McNeel,et al.  Androgen deprivation and immunotherapy for the treatment of prostate cancer. , 2017, Endocrine-related cancer.

[28]  Stefano Bonini,et al.  TFOS DEWS II pathophysiology report. , 2017, The ocular surface.

[29]  S. Aggarwal,et al.  Dry Eye Syndrome in Menopause and Perimenopausal Age Group , 2017, Journal of mid-life health.

[30]  K. Lam,et al.  A systematic review on the impact of diabetes mellitus on the ocular surface , 2017, Nutrition & Diabetes.

[31]  Mitchell A Jackson,et al.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment , 2017, Current opinion in ophthalmology.

[32]  A. Aprikian,et al.  Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. , 2016, European urology.

[33]  A. Sasse,et al.  Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis , 2015, International braz j urol : official journal of the Brazilian Society of Urology.

[34]  Susan Kovats,et al.  Estrogen receptors regulate innate immune cells and signaling pathways , 2015, Cellular immunology.

[35]  W. Feuer,et al.  Androgen deficiency and dry eye syndrome in the aging male. , 2014, Investigative ophthalmology & visual science.

[36]  A. Kheirkhah,et al.  Prevalence of dry eye syndrome in an adult population , 2014, Clinical & experimental ophthalmology.

[37]  U. Tunn,et al.  Safety and tolerability of intermittent androgen deprivation therapy: A literature review , 2012, International journal of urology : official journal of the Japanese Urological Association.

[38]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[39]  Ronald Klein,et al.  Long-term Incidence of Dry Eye in an Older Population , 2008, Optometry and vision science : official publication of the American Academy of Optometry.

[40]  Q. Cai,et al.  Estrogen-Induced Generation of Reactive Oxygen and Nitrogen Species, Gene Damage, and Estrogen-Dependent Cancers , 2007, Journal of toxicology and environmental health. Part B, Critical reviews.

[41]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[43]  M. Dana,et al.  Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? , 1999, Investigative ophthalmology & visual science.